25 Sep '15
Oleg Kouzbit, Online News Managing Editor
In a further onslaught on cancer Russia’s Avionco from outside Moscow is pushing its brand new drug candidate that the developer hopes will successfully fight androgen-independent prostate tumors. Backed by the RF government, Avionco began clinical trials last year.
Over the past few years Avionco is said to have been developing and testing its next gen androgen receptor antagonist designated “OHC1-0013B”—a drug candidate that the company believes will make a huge difference in treating what physicians refer to as castration-resistant prostate cancer.
A deadly enemy of many men over 50, the deleterious neoplasm is also considered a most ‘elusive’ form of prostate cancer that has denied scientists any means of countering it so far. At early stages, the killer barely reveals itself, biding its time to eventually evolve into its castration-resistant form. At the metastatic stage, prostate cancer has thus far been labeled “incurable.”
The results of preclinical trials a few years ago led Avionco to believe the candidate effectively inhibits androgen-dependent gene expression and deters the proliferation of malignant cells. These proven therapeutic properties were thought to be superior to a number of androgen receptor antagonists currently in clinical use, including bicalutamide.
Located in the town of Khimki just outside Moscow, Avionco is a biomed start-up established to focus on the development of innovative cancer therapies. In its research the company teams up with Khimki’s Research Institute for Chemical Diversity, a privately owned center for experimental oncology that reportedly develops cancer simulation techniques and does extensive preclinical trials of candidate molecules.
ChemRar, its parent firm, is one of Russia’s largest private biomed R&D centers with a presence in the US, European and South-East Asian pharma markets.
Prostate cancer now ranks fourth-to-second among most common malignancies in men, according to contrasting estimations, and is believed to be the fifth most frequently diagnosed cancer overall.
World Cancer Research Fund reports that each year about 400,000 new cases are diagnosed, with more than half registered in the United States alone. Nearly three-quarters of the recorded cases occur in developed countries.
In Russia, the incidence of prostate cancer is still believed to account for about 30% of that in the United States; however, its mortality rate is growing and may draw level with America and Europe within years, calling for Russia’s urgent moves to stop the “males’ bane.”
An estimated six million new cancer cases are diagnosed globally each year, including all forms of prostate cancer. Marchmont News will follow this and other cancer-focused developments.